Efficacy of TTMPB in Adult Cardiac Surgery

Inclusion Criteria: * Direct informed consent as documented by signature * Major adult (≥ 18 years old) with body weight ≥ 50 kg. For the record, fifty kilograms is the minimal weight to ensure that participants remain safely away from maximal doses of LA (3 mg/kg) * Planned and primary cardiac surgery via a sternotomy approach * Planned for ultra-fast-track procedure (i.e. postoperative extubation time of maximum two hours) Exclusion Criteria: * Participation in another study with investigational drug within the 30 days preceding and during the present study * Refusal and/or inability to understand or sign the informed consent * Emergent cardiac surgery * Previous cardiac surgery * Known hypersensitivity or true allergy to bupivacaine and other amide-class LA * Chronic pain history * Substance abuse history * Inability to follow the procedures of the study (e.g. due to language problems, psychological / psychiatric disorders, dementia) * Clinically significant concomitant diseases: severe cardiac dysfunction (i.e. LVEF ≤ 35%); severe chronic obstructive pulmonary disease (i.e. FEV \< 50%); severe hepatic disease. * Severe obesity (BMI \> 35kg/m2)